We are live on ! Find out more
SSA

Schonfeld Strategic Advisors Portfolio holdings

AUM $14.2B
1-Year Est. Return 37.17%
This Fund
S&P 500
This Quarter Est. Return
+24.53%
1 Year Est. Return
+37.17%
3 Year Est. Return
+107.74%
5 Year Est. Return
+136.38%
10 Year Est. Return
+1,412.31%
AUM
$7.44B
AUM Growth
+$2.18B
Cap. Flow
+$1.12B
Cap. Flow %
15.11%
Top 10 Hldgs %
13.07%
Holding
2,045
New
726
Increased
371
Reduced
415
Closed
520

Sector Composition

Rank Sector Weight
1 Financials 19.3%
2 Technology 16.73%
3 Consumer Discretionary 13.16%
4 Industrials 8.74%
5 Healthcare 7.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HUSN
1501
DELISTED
Hudson Capital Inc. Ordinary Shares
HUSN
$46K ﹤0.01%
+5,675
New +$24.4K
TPST icon
1502
Tempest Therapeutics
TPST
$14.4M
$44K ﹤0.01%
106
-56
-35% -$19.4K
MTL
1503
DELISTED
Mechel PAO American Depository Shares, each representing two ordinary shares (ADSs)
MTL
$42K ﹤0.01%
+20,600
New +$32.5K
AEMD icon
1504
Aethlon Medical
AEMD
$1.59M
$41K ﹤0.01%
+4
New +$26.7K
AXAS
1505
DELISTED
Abraxas Petroleum Corp
AXAS
$40K ﹤0.01%
+17,700
New +$41.4K
TTOO
1506
DELISTED
T2 Biosystems, Inc
TTOO
$39K ﹤0.01%
+6
New +$36.7K
BW icon
1507
Babcock & Wilcox
BW
$1.4B
$38K ﹤0.01%
+10,684
New +$33.5K
NINE
1508
DELISTED
Nine Energy Service
NINE
$36K ﹤0.01%
+13,300
New +$24.5K
SLNO
1509
DELISTED
Soleno Therapeutics
SLNO
$36K ﹤0.01%
1,253
-1,374
-52% -$39.7K
TCRT icon
1510
Alaunos Therapeutics
TCRT
$4.86M
$36K ﹤0.01%
95
-336
-78% -$134K
VNTR
1511
DELISTED
Venator Materials PLC
VNTR
$34K ﹤0.01%
+10,316
New +$24.6K
IO
1512
DELISTED
ION Geophysical Corporation
IO
$34K ﹤0.01%
+14,000
New +$26.3K
PAVM icon
1513
PAVmed
PAVM
$35.4M
$33K ﹤0.01%
+35
New +$29.9K
TRVN
1514
DELISTED
Trevena, Inc.
TRVN
$33K ﹤0.01%
+25
New +$39.8K
LCTX icon
1515
Lineage Cell Therapeutics
LCTX
$282M
$32K ﹤0.01%
+17,733
New +$24.8K
OPTT icon
1516
Ocean Power Technologies
OPTT
$47.8M
$32K ﹤0.01%
+11,800
New +$26.5K
STR
1517
DELISTED
Sitio Royalties
STR
$32K ﹤0.01%
+2,500
New +$25.4K
OIG
1518
DELISTED
Orbital Infrastructure Group, Inc. Common Stock
OIG
$28K ﹤0.01%
+320
New +$13.7K
VRN
1519
DELISTED
Veren
VRN
$24K ﹤0.01%
+10,400
New +$17.8K
AMPE
1520
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$24K ﹤0.01%
+52
New +$17.1K
SRGA
1521
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$23K ﹤0.01%
353
-8,944
-96% -$583K
ADOCR
1522
CALL
DELISTED
Edoc Acquisition Corp. Right
ADOCR
$15K ﹤0.01%
+24,550
New +$9.1K
WHWK
1523
Whitehawk Therapeutics
WHWK
$232M
$12K ﹤0.01%
+793
New +$17K
BREZR
1524
CALL
DELISTED
Breeze Holdings Acquisition Corp. Right
BREZR
$7K ﹤0.01%
+25,000
New +$6.78K
AAON icon
1525
Aaon
AAON
$7.39B
-11,550
Closed -$463K

Similar funds

Schonfeld Strategic Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, Schonfeld Strategic Advisors held 2,045 positions worth $7.44B, up 42% from $5.25B the previous quarter. Its ten largest holdings account for 13% of the portfolio.

Schonfeld Strategic Advisors deployed $1.12B of net new capital in Q4 2020, opening 726 new positions and adding to 371 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 272,911 shares worth $102M.

By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 15% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Crown Holdings, an estimated $43.8M trimmed.

  • Schonfeld Strategic Advisors's largest Q4 2020 buy was State Street SPDR S&P 500 ETF Trust: 272,911 shares worth $102M.
  • Schonfeld Strategic Advisors added most to US Bancorp in Q4 2020, an estimated $62.4M increase.
  • Schonfeld Strategic Advisors's biggest Q4 2020 reduction was Crown Holdings, cutting an estimated $43.8M.
  • Schonfeld Strategic Advisors fully exited Claritev Corp in Q4 2020, selling an estimated $30.8M.
  • Schonfeld Strategic Advisors's ten largest holdings make up 13% of its $7.44B portfolio in Q4 2020.
  • Schonfeld Strategic Advisors opened 726 new positions and closed 520 in Q4 2020.
  • Schonfeld Strategic Advisors's portfolio value rose 42% quarter-over-quarter to $7.44B.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.